Published 2 months ago • loading... • Updated 2 months ago

PTC Therapeutics Submits Vantiquinone NDA to FDA

Summary by contractpharma.com

Evidence of efficacy and safety data support the potential for vatiquinone to fill the significant unmet need for patients living with Friedreich ataxia.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All

Left

Center

Right

contractpharma.com

PTC Therapeutics Submits Vantiquinone NDA to FDA

Evidence of efficacy and safety data support the potential for vatiquinone to fill the significant unmet need for patients living with Friedreich ataxia.

2 months ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left0Leaning Right0Center0Last Updated2 months agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

contractpharma.com broke the news in 2 months ago on Thursday, December 19, 2024.

Sources are mostly out of (0)

PTC Therapeutics Submits Vantiquinone NDA to FDA

1 Articles

1 Articles

PTC Therapeutics Submits Vantiquinone NDA to FDA

PTC Therapeutics Submits Vantiquinone NDA to FDA

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics